69 results
8-K
EX-99.1
w02idva36nossuf
13 Nov 23
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
12:00am
8-K
EX-99.1
r74u9db8wvth
3 Oct 23
Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026
4:14pm
PRE 14A
rm6rt3 3l
17 Apr 23
Preliminary proxy
4:11pm
8-K
EX-99.1
d78j8c gph
3 Nov 22
Other Events
1:56pm
8-K
EX-99.1
n8g446
11 Aug 22
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
4:04pm
8-K
EX-99.2
fm07zt r19r
27 Jun 22
Regulation FD Disclosure
4:25pm
8-K
EX-99.1
top3it8pmj qfz
12 May 22
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
zgnt0v
3 May 22
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
4:08pm